Trials / Completed
CompletedNCT04476108
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3016859 | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2020-07-15
- Primary completion
- 2021-07-08
- Completion
- 2021-11-11
- First posted
- 2020-07-17
- Last updated
- 2023-11-14
- Results posted
- 2022-08-03
Locations
36 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04476108. Inclusion in this directory is not an endorsement.